153 related articles for article (PubMed ID: 25662405)
1. Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma.
Klein O; Davis ID; McArthur GA; Chen L; Haydon A; Parente P; Dimopoulos N; Jackson H; Xiao K; Maraskovsky E; Hopkins W; Stan R; Chen W; Cebon J
Cancer Immunol Immunother; 2015 Apr; 64(4):507-18. PubMed ID: 25662405
[TBL] [Abstract][Full Text] [Related]
2. Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™.
Nicholaou T; Chen W; Davis ID; Jackson HM; Dimopoulos N; Barrow C; Browning J; Macgregor D; Williams D; Hopkins W; Maraskovsky E; Venhaus R; Pan L; Hoffman EW; Old LJ; Cebon J
Cancer Immunol Immunother; 2011 Nov; 60(11):1625-37. PubMed ID: 21698545
[TBL] [Abstract][Full Text] [Related]
3. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.
Nicholaou T; Ebert LM; Davis ID; McArthur GA; Jackson H; Dimopoulos N; Tan B; Maraskovsky E; Miloradovic L; Hopkins W; Pan L; Venhaus R; Hoffman EW; Chen W; Cebon J
Clin Cancer Res; 2009 Mar; 15(6):2166-73. PubMed ID: 19276262
[TBL] [Abstract][Full Text] [Related]
4. Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma.
Cebon JS; Gore M; Thompson JF; Davis ID; McArthur GA; Walpole E; Smithers M; Cerundolo V; Dunbar PR; MacGregor D; Fisher C; Millward M; Nathan P; Findlay MPN; Hersey P; Evans TRJ; Ottensmeier CH; Marsden J; Dalgleish AG; Corrie PG; Maria M; Brimble M; Williams G; Winkler S; Jackson HM; Endo-Munoz L; Tutuka CSA; Venhaus R; Old LJ; Haack D; Maraskovsky E; Behren A; Chen W
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317292
[TBL] [Abstract][Full Text] [Related]
5. Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.
Pavlick A; Blazquez AB; Meseck M; Lattanzi M; Ott PA; Marron TU; Holman RM; Mandeli J; Salazar AM; McClain CB; Gimenez G; Balan S; Gnjatic S; Sabado RL; Bhardwaj N
Cancer Immunol Res; 2020 Jan; 8(1):70-80. PubMed ID: 31699709
[TBL] [Abstract][Full Text] [Related]
6. NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus.
Chen JL; Dawoodji A; Tarlton A; Gnjatic S; Tajar A; Karydis I; Browning J; Pratap S; Verfaille C; Venhaus RR; Pan L; Altman DG; Cebon JS; Old LL; Nathan P; Ottensmeier C; Middleton M; Cerundolo V
Int J Cancer; 2015 Mar; 136(6):E590-601. PubMed ID: 25081390
[TBL] [Abstract][Full Text] [Related]
7. Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient.
Tsuji K; Hamada T; Uenaka A; Wada H; Sato E; Isobe M; Asagoe K; Yamasaki O; Shiku H; Ritter G; Murphy R; Hoffman EW; Old LJ; Nakayama E; Iwatsuki K
Cancer Immunol Immunother; 2008 Oct; 57(10):1429-37. PubMed ID: 18311489
[TBL] [Abstract][Full Text] [Related]
8. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery.
Schnurr M; Chen Q; Shin A; Chen W; Toy T; Jenderek C; Green S; Miloradovic L; Drane D; Davis ID; Villadangos J; Shortman K; Maraskovsky E; Cebon J
Blood; 2005 Mar; 105(6):2465-72. PubMed ID: 15546948
[TBL] [Abstract][Full Text] [Related]
9. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.
Davis ID; Chen W; Jackson H; Parente P; Shackleton M; Hopkins W; Chen Q; Dimopoulos N; Luke T; Murphy R; Scott AM; Maraskovsky E; McArthur G; MacGregor D; Sturrock S; Tai TY; Green S; Cuthbertson A; Maher D; Miloradovic L; Mitchell SV; Ritter G; Jungbluth AA; Chen YT; Gnjatic S; Hoffman EW; Old LJ; Cebon JS
Proc Natl Acad Sci U S A; 2004 Jul; 101(29):10697-702. PubMed ID: 15252201
[TBL] [Abstract][Full Text] [Related]
10. Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.
Sabado RL; Pavlick A; Gnjatic S; Cruz CM; Vengco I; Hasan F; Spadaccia M; Darvishian F; Chiriboga L; Holman RM; Escalon J; Muren C; Escano C; Yepes E; Sharpe D; Vasilakos JP; Rolnitzsky L; Goldberg J; Mandeli J; Adams S; Jungbluth A; Pan L; Venhaus R; Ott PA; Bhardwaj N
Cancer Immunol Res; 2015 Mar; 3(3):278-287. PubMed ID: 25633712
[TBL] [Abstract][Full Text] [Related]
11. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF.
Sharma P; Bajorin DF; Jungbluth AA; Herr H; Old LJ; Gnjatic S
J Immunother; 2008; 31(9):849-57. PubMed ID: 18833002
[TBL] [Abstract][Full Text] [Related]
12. A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant.
Davis ID; Quirk J; Morris L; Seddon L; Tai TY; Whitty G; Cavicchiolo T; Ebert L; Jackson H; Browning J; MacGregor D; Wittke F; Winkels G; Alex R; Miloradovic L; Maraskovsky E; Chen W; Cebon J
Immunotherapy; 2017 Mar; 9(3):249-259. PubMed ID: 28183192
[TBL] [Abstract][Full Text] [Related]
13. NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells.
Gnjatic S; Altorki NK; Tang DN; Tu SM; Kundra V; Ritter G; Old LJ; Logothetis CJ; Sharma P
Clin Cancer Res; 2009 Mar; 15(6):2130-9. PubMed ID: 19276258
[TBL] [Abstract][Full Text] [Related]
14. Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients.
Kageyama S; Wada H; Muro K; Niwa Y; Ueda S; Miyata H; Takiguchi S; Sugino SH; Miyahara Y; Ikeda H; Imai N; Sato E; Yamada T; Osako M; Ohnishi M; Harada N; Hishida T; Doki Y; Shiku H
J Transl Med; 2013 Oct; 11():246. PubMed ID: 24093426
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients.
Sabbatini P; Tsuji T; Ferran L; Ritter E; Sedrak C; Tuballes K; Jungbluth AA; Ritter G; Aghajanian C; Bell-McGuinn K; Hensley ML; Konner J; Tew W; Spriggs DR; Hoffman EW; Venhaus R; Pan L; Salazar AM; Diefenbach CM; Old LJ; Gnjatic S
Clin Cancer Res; 2012 Dec; 18(23):6497-508. PubMed ID: 23032745
[TBL] [Abstract][Full Text] [Related]
16. A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma.
Ebert LM; MacRaild SE; Zanker D; Davis ID; Cebon J; Chen W
PLoS One; 2012; 7(10):e48424. PubMed ID: 23110239
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients.
Kitano S; Tsuji T; Liu C; Hirschhorn-Cymerman D; Kyi C; Mu Z; Allison JP; Gnjatic S; Yuan JD; Wolchok JD
Cancer Immunol Res; 2013 Oct; 1(4):235-44. PubMed ID: 24396833
[TBL] [Abstract][Full Text] [Related]
18. Epitope hierarchy of spontaneous CD4+ T cell responses to LAGE-1.
Kudela P; Sun Z; Fourcade J; Janjic B; Kirkwood JM; Maillere B; Zarour HM
J Immunol; 2011 Jan; 186(1):312-22. PubMed ID: 21131422
[TBL] [Abstract][Full Text] [Related]
19. Circulating CD4+ T cells that produce IL4 or IL17 when stimulated by melan-A but not by NY-ESO-1 have negative impacts on survival of patients with stage IV melanoma.
Zelba H; Weide B; Martens A; Derhovanessian E; Bailur JK; Kyzirakos C; Pflugfelder A; Eigentler TK; Di Giacomo AM; Maio M; Aarntzen EH; de Vries J; Sucker A; Schadendorf D; Büttner P; Garbe C; Pawelec G
Clin Cancer Res; 2014 Aug; 20(16):4390-9. PubMed ID: 24938524
[TBL] [Abstract][Full Text] [Related]
20. Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma.
Butterfield LH; Vujanovic L; Santos PM; Maurer DM; Gambotto A; Lohr J; Li C; Waldman J; Chandran U; Lin Y; Lin H; Tawbi HA; Tarhini AA; Kirkwood JM
J Immunother Cancer; 2019 Apr; 7(1):113. PubMed ID: 31014399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]